Metallothionein-2: An emerging target in inflammatory diseases and cancers.

Xue-Ling Wang, Michael Schnoor, Lei-Miao Yin

Journal: Pharmacology & therapeutics 2023;244():108374

PMID: 36889441

Full Text on Elsevier Science View on PubMed

Abstract

Metallothionein-2 (MT-2) was originally discovered as a mediator of zinc homeostasis and cadmium detoxification. However, MT-2 has recently received increased attention because altered expression of MT-2 is closely related to various diseases such as asthma and cancers. Several pharmacological strategies have been developed to inhibit or modify MT-2, revealing its potential as drug target in diseases. Therefore, a better understanding of the mechanisms of MT-2 action is warranted to improve drug development for potential clinical applications. In this review, we highlight recent advances in determining the protein structure, regulation, binding partners, and new functions of MT-2 in inflammatory diseases and cancers.

Address: Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China.; Department of Molecular Biomedicine, Center for Investigation and Advanced Studies of the National Polytechnic Institute (Cinvestav-IPN), Avenida IPN 2508, 07360 Mexico City, Mexico.; Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China. Electronic address: [email protected].

DOI: 10.1016/j.pharmthera.2023.108374

Link outs

Free resources

Medical:

https://medlineplus.gov/cancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Zinc, Metallothionein, Neoplasms, Cadmium